Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Aurora, CO
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
New Haven, CT
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Washington,
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Boca Raton, FL
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Jacksonville, FL
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Orlando, FL
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Baltimore, MD
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Rochester, MN
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Las Vegas, NV
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Albany, NY
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
New York, NY
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Springfield, OR
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Springfield, OR
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Charleston, SC
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Nashville, TN
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Bedford, TX
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Dallas, TX
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
McAllen, TX
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
The Woodlands, TX
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Webster, TX
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Fairfax, VA
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Hampton, VA
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Hampton, VA
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Seattle, WA
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Wenatchee, WA
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Study of Nesvacumab (REGN910/ SAR307746)
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
San Francisco, CA
Study of Nesvacumab (REGN910/ SAR307746)
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Nesvacumab (REGN910/ SAR307746)
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
San Antonio, TX
Study of Nesvacumab (REGN910/ SAR307746)
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Urology Center of Colorado
mi
from
Denver, CO
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Emroy University
mi
from
Atlanta, GA
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Emroy University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Johns Hopkins Hosp
mi
from
Baltimore, MD
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Johns Hopkins Hosp
mi
from
Baltimore, MD
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Washington University
mi
from
St. Louis, MO
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Thomas Jefferson University
mi
from
Philadelphia, PA
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
Baylor College of Medicine
mi
from
Houston, TX
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
University of Texas Health Science Center
mi
from
San Antonio, TX
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
University of Virginia
mi
from
Charlottesville, VA
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated:  9/13/2013
University of Wisconsin
mi
from
Madison, WI
Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
Status: Enrolling
Updated: 9/13/2013
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated:  9/18/2013
John Hopkins Medical Center
mi
from
Baltimore, MD
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated: 9/18/2013
John Hopkins Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated:  9/18/2013
Dartmouth Medical Center
mi
from
Lebanon, NH
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated: 9/18/2013
Dartmouth Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated:  9/18/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated: 9/18/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated:  9/18/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument
Status: Enrolling
Updated: 9/18/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  9/20/2013
Translational Genomics Research Institute (TGen)
mi
from
Scottsdale, AZ
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 9/20/2013
Translational Genomics Research Institute (TGen)
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  9/20/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 9/20/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  9/20/2013
Univ of Pennsylvania
mi
from
Philadelphia, PA
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 9/20/2013
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Status: Enrolling
Updated:  9/21/2013
Commonwealth Hematology-Oncology
mi
from
Lawrence, MA
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Status: Enrolling
Updated: 9/21/2013
Commonwealth Hematology-Oncology
mi
from
Lawrence, MA
Click here to add this to my saved trials
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging
Status: Enrolling
Updated:  9/23/2013
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging
Status: Enrolling
Updated: 9/23/2013
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
Ann & Rober H Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
Ann & Rober H Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated:  9/23/2013
Riley Hospital for Children
mi
from
Indianapolis, IN
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study
Status: Enrolling
Updated: 9/23/2013
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials